The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 3×
“This has resulted in a number of approved liposomal drug products including Doxil ® , DaunoXome ® , DepoCyt ® , Myocet ® , Lipo-dox ® , and Marqibo ® (16-32).”
BackgroundDiffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
Cited by
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 810
Gavilán, H., Avugadda, S. K., Fernández-Cabada, T., Soni, N., Cassani, M., Mai, B. T., Chantrell, R., & Pellegrino, T. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00427a · Cited by 525
Recent progress in nanomedicine for enhanced cancer chemotherapy
Wei, G., Wang, Y., Yang, G., Wang, Y., & Ju, R. (2021) · Theranostics · doi:10.7150/thno.57828 · Cited by 463
Wolfram, J., & Ferrari, M. (2019) · Nano Today · doi:10.1016/j.nantod.2019.02.005 · Cited by 436
Cancer drug delivery in the nano era: An overview and perspectives
Li, Z., Tan, S., Li, S., Shen, Q., & Wang, K. (2017) · Oncology Reports · doi:10.3892/or.2017.5718 · Cited by 406
Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies
Soetaert, F., Korangath, P., Serantes, D., Fiering, S., & Ivkov, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.025 · Cited by 406
Development of Pharmaceutical Nanomedicines: From the Bench to the Market
Halwani, A. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010106 · Cited by 324
Progress, challenges, and future of nanomedicine
Zhang, C., Yan, L., Wang, X., Zhu, S., Chen, C., Gu, Z., & Zhao, Y. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101008 · Cited by 318
Lammers, T. (2024) · Advanced Materials · doi:10.1002/adma.202312169 · Cited by 290
Li, J., & Kataoka, K. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c09029 · Cited by 281
Cancer nanotechnology: current status and perspectives
Kemp, J. A., & Kwon, Y. J. (2021) · Nano Convergence · doi:10.1186/s40580-021-00282-7 · Cited by 266
Lipid-based nanoparticle technologies for liver targeting
Böttger, R., Pauli, G., Chao, P.-H., AL Fayez, N., Hohenwarter, L., & Li, S.-D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.017 · Cited by 264
Rational Design of Biomaterials to Potentiate Cancer Thermal Therapy
Zhu, Y., Li, Q., Wang, C., Hao, Y., Yang, N., Chen, M., Ji, J., Feng, L., & Liu, Z. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00822 · Cited by 163
Thermoresponsive M1 macrophage-derived hybrid nanovesicles for improved in vivo tumor targeting
Barone, A., Zimbo, A. M., d’Avanzo, N., Tolomeo, A. M., Ruga, S., Cardamone, A., Celia, C., Scalise, M., Torella, D., La Deda, M., et al. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01378-9 · Cited by 22
Metadata
- Authors
- Dou, Y., Hynynen, K., & Allen, C.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 249
- Pages
- 63-73
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2580036324
- Cited by
- 210
- References
- 2
- FWCI
- 7.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.